# A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

> **NCT06644781** · PHASE3 · RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 510 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Ifinatamab deruxtecan
- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel
- **DRUG:** Irinotecan hydrochloride (HCl)

## Key facts

- **NCT ID:** NCT06644781
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2028-06-01
- **Final completion:** 2029-11-01
- **Target enrollment:** 510 (ESTIMATED)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06644781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06644781, "A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06644781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*